(Q34481826)

2 August 2017

1 reference

title

Novel angiotensin II inhibitors in cardiovascular medicine (English)

1 reference

2 August 2017

Burnier M

1

1 reference

2 August 2017

language of work or name

English

0 references

publication date

1 November 2001

1 reference

Expert Opinion on Investigational Drugs

2 August 2017

published in

1 reference

2 August 2017

volume

10

1 reference

2 August 2017

issue

11

1 reference

2 August 2017

page(s)

1957-1964

1 reference

A specific orally active inhibitor of angiotensin-converting enzyme in man.

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.11.1957

Congestive heart failure in normotensive man. Haemodynamics, renin, and angiotensin II blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.11.1957

Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.11.1957

Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.11.1957

Current strategies for retarding progression of renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.11.1957

Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.11.1957

Human renin inhibitor peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.11.1957

Angiotensin II type 1 receptor blockers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.11.1957

Rationale and design of the Valsartan Heart Failure Trial: a large multinational trial to assess the effects of valsartan, an angiotensin-receptor blocker, on morbidity and mortality in chronic congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.11.1957

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.11.1957

The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.11.1957

Bioavailability of repeated oral administration of MDL 100,240, a dual inhibitor of angiotensin-converting enzyme and neutral endopeptidase in healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.11.1957

10.1517/13543784.10.11.1957

21 January 2018

Identifiers

DOI

1 reference

2 August 2017

1 reference